Detection of minimal residual disease using circulating tumor DNA in solid tumors:potential and challenges / 中华检验医学杂志

ABSTRACT

With the improvement of detective sensitivity, the application of circulating tumor DNA (ctDNA) has gradually expanded from advanced tumors to early stage. Recently, the detection of minimal residual disease (MRD) using ctDNA in solid tumors has attracted particular attention. MRD testing has shown an essential role in the risk assessment of solid tumor recurrence and treatment guidance. However, the MRD detection strategies used in each study are different, and the conclusions drawn as well. This paper reviewed the research progress of ctDNA for MRD detection in solid tumor, as well as its challenges of detection technology and application, in order to promote the clinical transformation and standardized application of MRD detection by ctDNA in solid tumors.